RxDoctor Payments Data

Velma Scantlebury, MD

General Practice · Newark, DENPI 1487608667

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,260 of the $21,783 with a category attached, or 60.9%. 15 manufacturers reported payments, led by Merck at 35.6% of the total. Reporting peaked in 2021 at $7,160 and has fallen 97.7% since, to $164 in 2025. Among general practice clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,783in general payments, 2019–2025

Across 41 payments — averaging $531.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$8K
  • Sanofi-aventis U.S. LLC$6K
  • Intuitive Surgical$5K
  • Veloxis Pharmaceuticals, Inc.$3K
  • AstraZeneca$547
  • Viiv Healthcare Company$89
  • plus $280 from 9 others

What the payments were for

  • Consulting fees$13,26061%
  • Speaking & faculty fees$2,30011%
  • Travel & lodging$1501%
  • Food & beverage$1,6237%
  • Education$4,00018%
  • Charitable contribution$4502%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,783 in reported general payments places this provider in the 95th percentile of 214 general practice providers in Delaware.

See all general practice providers in Delaware

Medicare billing

Part B allowed, 2024
$9,297
Medicare patients
32
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$23,511
Gabapentin38$833
Atorvastatin Calcium36$568
Potassium Chloride11$503
Omeprazole21$283
Famotidine15$279
Amlodipine Besylate34$278
Metformin Hcl43$222
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$170
Donepezil Hcl16$154
Lisinopril17$118
Losartan Potassium14$87
Fluoxetine Hcl12$66
Hydrochlorothiazide12$40
Pravastatin Sodium12$26

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$23,51121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 214 general practice providers in Delaware.

Other general practice in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →